BRANSON, Mo. - TelAve -- Metavalis Inc, a strategic bioengineering firm situated at the intersection of synthetic biology and national defense, today announced the appointment of Aman Khera, EMBA, FRAPS, FTOPRA, as the first official member of its Scientific Advisory Board (SAB). Khera will serve as the company's Regulatory Science, Innovation, and Compliance Advisor.

This appointment signals a critical maturation in the Metavalis operational strategy. As the company advances its dual use pipeline comprising of The Stealth LNP therapeutic platform and the Project Omega neural interface it requires a regulatory architecture as advanced as its technology.

Khera, widely recognized in the life sciences industry as the "Rebel Regulator," brings nearly three decades of global leadership experience. She is a Fellow of both the Regulatory Affairs Professionals Society (FRAPS) and The Organisation for Professionals in Regulatory Affairs (FTOPRA) the highest credentials in the field.

More on TelAve News

• Aleen Inc. (C S E: ALEN.U) Advances Digital Wellness Vision with Streamlined Platform Navigation and Long-Term Growth Strategy
• RimbaMindaAI Officially Launches Version 3.0 Following Strategic Breakthrough in Malaysian Market Analysis
• Fed Rate Pause & Dow 50k: Irfan Zuyrel on Liquidity Shifts, Crypto Volatility, and the ASEAN Opportunity
• 20/20 Institute Launches Updated Vision Correction Procedures Page for Denver & Colorado Springs
• OneVizion Announces Next Phase of Growth as Brad Kitchens Joins Board of Directors

"We are building something at Metavalis that does not fit into a standard regulatory box," stated Jordan Bekemeier, Founder of Metavalis Inc. "When you are architecting re-dosable genetic medicines and solid-state neural preservation systems, you cannot rely on the old guard of regulatory thinking. You need someone who understands the rules well enough to rewrite them for the future. You need a Rebel."

Aman Khera will lead the regulatory strategy for:

The "Lumina" Program: Navigating the expedited pathways for the company's lead orphan drug asset for Crigler-Najjar Syndrome Type 1.

The Cardinal Physics Kernel: Establishing the compliance framework for the company's proprietary AI and physics based simulation environments.

Digital Health Integration: Leveraging her expertise at the intersection of Healthcare, AI, and Digital Health to bridge the gap between biological and optical computing.

"We didn't choose Aman just for her formidable resume, we chose her because she runs toward the future while others shy away from it," Bekemeier added. "Her mission is to ensure innovation actually reaches the people who need it. That aligns perfectly with our Warrior Ethos."

More on TelAve News

• New Children's Picture Book "Diwa of Mount Luntian" Focuses on Calm, Culture, and Connection for Today's Families
• Actor, Spokesperson Rio Rocket Featured in "Switch to AT&T" Campaign Showing How Customers Can BYOD and Keep Their Number
• The World's No.1 Superstar® Brings Disco Fever Back With New Global Single and Video "Disco Dancing"
• Boston Industrial Solutions' Natron® 512N Series UV LED Ink Achieves BPA Certification, Advancing Safe and Sustainable Digital Printing
• Joan Nissen promoted to Century Fasteners Corp. – General Manager, Aerospace & Government Sales

About Aman Khera Aman Khera is a globally recognized regulatory strategist, patient champion, and PharmaVoice 100 Honoree. With a career spanning nearly 30 years, she has guided complex therapeutics from early strategy to commercialization. She is a pragmatic strategist known for challenging conventional norms to accelerate patient access to life saving innovations.

Check Out What We Are Building At

https://metavalis.com/

Check Us Out On Crunchbase At

https://www.crunchbase.com/organization/metavalis